Phase 1 & 2 Study Reveals CoronaVac COVID-19 Vaccine Candidate Inferior to BNT162B2 & mRNA-1273

Phase 1 & 2 Study Reveals CoronaVac COVID-19 Vaccine Candidate Inferior to BNT162B2 & mRNA-1273

A Chinese firm, known as Sinovac, one of the leading COVID-19 vaccine developer contenders, recently revealed results from a peer-reviewed paper in the medical journal The Lancet. Collected from its first Phase 1 and Phase 2 clinical trials investigating the inactivated vaccine known as CoronaVac, these first studies sought to demonstrate the safety and immunogenicity of CoronaVac: that is, the experimental vaccine sponsor’s testing of the product’s ability to trigger an immune response, as well as the monitoring of any side-effects, including adverse events. The study sponsor clinical trial design incorporated a couple of different dosages and inoculation schedules. This class of vaccine, inactivated, represents more of a traditional approach when compared to the more technologically novel messenger RNA-based vaccine candidates developed by Moderna (mRNA-1273) and Pfizer/BioNTech (BNT162b3). Currently, there is no approved mRNA-based vaccine; however, Pfizer just filed for an emergency use authorization (EUA) with the U.S. Food and Drug Administration (FDA) based on the existing results thus far. The results evidence some benefits but, overall, are considered inferior to the two ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee